Abstract HIV-1-associated neurocognitive disorders (HAND) is associated with blood-brain-barrier (BBB) inflammation, and inflammation involves toll-like receptors (TLRs) signaling. It is not known whether primary human brain microvascular endothelial cells (HBMEC), the major BBB component, express TLRs or whether TLRs are involved in BBB dysfunction and HAND. We demonstrate that HBMEC express TLR3, 4, 5, 7, 9, and 10, and TLR3 was the most abundant. HIV-1 and TLR3 activation increased endothelial TLR3 transcription and expression. HIV-1-positive human subjects showed significantly higher TLR3 expression in brain tissues and blood vessels, with higher TLR3 levels in subjects with HAND. HIV-1 and TLR3 activation increased endothelial IL6 expression by 6-to-127-fold (P < 0.001), activated cjun(serine-63) and SAPK/JNK(Thr183/Tyr185). HIV-1 upregulated IL6 through interleukin-1 receptor-associatedkinase (IRAK)-1/4/TAK1/JNK pathways, via ATPdependent JNK activation. TLR3 activation upregulated IL6 through TAK1/JNK pathways, via ATP-dependent orindependent JNK activation. HIV-1 and TLR3 activation also upregulated transcription factors associated with IL6 and TAK1/JNK pathways (Jun, CEBPA, STAT1). Blocking TLR3 activation prevented HIV-1-and TLR3 ligandsinduced upregulation of these transcription factors, prevented IL6 transcription and expression, c-jun and JNK activation. HIV-1 and TLR3 ligands significantly increased monocytes adhesion and migration through the BBB, and decreased endothelial claudin-5 expression. Blocking TLR3 and JNK activation prevented HIV-1-and TLR3 ligands-induced claudin-5 downregulation, monocytes adhesion and transendothelial migration. These data suggest that viral immune recognition via endothelial TLR3 is involved in endothelial inflammation and BBB dysfunction in HIV/AIDS and HAND. Our data provides novel insights into the molecular basis of these HIV-1-and TLR3-mediated effects.
Background
Toll-like receptors (TLRs) are pattern-recognition receptors that detect invading pathogens via their pathogen associated molecular patterns (PAMP), and the resulting TLR/PAMP interaction triggers the innate immune system [1, 2] . Thus, TLRs play a major role in innate immunity. Thirteen different TLRs have been discovered so far, of which 11 (TLR1 to TLR11) are expressed in human cells [3, 4] . TLR1, 2, 4, 5, 6, and 10 are mostly expressed on the outer cell membranes, whereas TLR3, 7, 8, and 9 are mostly expressed on endosomal membranes [3, 4] . However, the localization of TLRs vary amongst cell types; TLR3 is often located intracellularly on endosomes in many cells, but in human astrocytes TLR3 is expressed both intracellularly and on the cell surface [5] . TLR3 can be activated by viral double-stranded RNA (dsRNA) [6] , viral single-stranded RNA (ssRNA) [7] , endogenous viral mRNA [8] , and polyinosinic-polycytidylic acid (PIC), a synthetic analogue of viral dsRNA [9] . It has been demonstrated that viral dsRNA is a replication intermediate of several ssRNA viruses; and that dsRNA are produced during the course of replication of ssRNA viruses such as the respiratory syncytial virus, encephalomyocarditis virus and West Nile virus, and activate TLR3 [10] [11] [12] .
Ligand-induced TLR activation can be beneficial since the TLR-ligand complex initiates a quick and protective innate immune response against invading pathogens [1, 2] . However, it can also be detrimental because uncontrolled and unregulated TLR activation can result in excessive inflammation, cell injury, and tissue damage [13] [14] [15] . In fact, TLR3 has been implicated in the pathogenesis of several viral infections, including HIV-1-and SIV-induced inflammation in lymph nodes and astrocytes [16, 17] , HIV-1 transactivation, replication, and inflammation [18, 19] . Human brain microvascular endothelial cells (HBMEC) are a major component of the blood-brain barrier (BBB). Under normal physiological conditions, HBMEC functions as an interface between the blood and the brain parenchyma, strictly regulating influx of ion molecules and leukocytes into the central nervous system (CNS) [20, 21] . During HIV-1 infection, the BBB function is compromised, and this may enable the entry of free virus and/or HIV-infected mononuclear phagocytes into the brain, infection of resident CNS cells and inflammation, and these may contribute to the development of HIV-1 associated neurocognitive disorders (HAND) [21] [22] [23] [24] . We previously showed that HIV-1-induced BBB dysfunction was associated with activation of proinflammatory cytokines and chemokines in HBMEC, and that IL6 and TLR signaling were major canonical pathways involved in this HIV-induced BBB inflammation [25, 26] . It is not known whether primary HBMEC express TLRs, and which of the 11 human TLRs may be involved in HIVinduced BBB dysfunction. In the present study, we identify the TLRs expressed in primary HBMEC. We show that HBMEC express TLR3, 4, 5, 7, 9, and 10, and TLR3 was the most abundant TLR expressed in HBMEC. Ex-vivo studies using human brain tissues confirmed these findings and showed significantly higher TLR3 transcription and expression in brain tissues of HIV-1-infected subjects, mostly on the brain blood vessels; with much higher TLR3 levels in brain tissues of subjects with HAND or HIV encephalitis (HIVE). We also showed that exposure of HBMEC to HIV-1 or the TLR3 ligand PIC increased TLR3 levels and IL6 expression via Transforming growth factor-β activated kinase-1 (TAK1) and c-Jun N-terminal kinase (JNK) pathways. Functional studies showed that both HIV-1 and PIC significantly increased monocytes adhesion and migration through in vitro BBB models, and decreased the expression of the endothelial tight junction protein claudin-5. The TLR3/dsRNA complex inhibitor, as well as JNK inhibitors blocked HIV-1-and PICinduced claudin-5 downregulation, monocytes adhesion and transendothelial migration. These data suggest that viral immune recognition via endothelial TLR3 is involved HIV-1-induced endothelial inflammation and BBB dysfunction; and that HIV-induced inflammation, BBB dysfunction and HAND are associated with increased TRL3 expression in the CNS and brain endothelium.
Materials and Methods

Brain Endothelial Cells (EC) Culture
Primary HBMEC were isolated from brain tissue obtained during surgical removal of epileptogenic cerebral cortex in adult patients, under an Institutional Review Board-approved protocol at the University of Arizona as described previously [27, 28] . Routine evaluation by immunostaining for vonWillebrand factor, Ulex europaeus lectin and CD31 showed that cells were > 99% pure. Freshly isolated cells were cultured in collagen-coated flasks or 6-well culture plates using Dulbecco's Modified Eagle Medium (DMEM)/F12 (Life Technologies, Grand Island, NY, USA) containing 10% fetal bovine serum (FBS, Atlanta Biologicals, Flowery Branch, GA, USA), supplemented with 10 mmol/l L-glutamine (Life Technologies), 1% heparin (Thermo Fisher Scientific, Pittsburgh, PA, USA), 1% endothelial cell growth supplement (ECGS; BD Bioscience, San Jose, CA, USA), 1% penicillinstreptomycin (Life Technologies), 1% fungizone (MP Biomedicals, Solon, OH, USA). Cells at passage 2 to 4 were used in this study.
Human Brain Tissues
Brain tissues (cortex) from HIV-1-seropositive patients with or without neurocognitive impairment, and HIV-1/2-seronegative controls were obtained from the National NeuroAIDS Tissue Consortium and the Department of Pharmacology and Experimental Neuroscience brain bank. The clinical histories of all brain tissue donors are detailed in Table 1 .
RNA Extraction and cDNA Synthesis
Confluent HBMEC in six-well plates were treated with high molecular weight PIC (50 μg/ml) (InvivoGen, San Diego, CA, USA) or HIV-1 ADA (multiplicity of infection, MOI: 0.01) for 2 to 24 h. Controls consisted of untreated cells and cells treated with similar concentrations of PIC or HIV-1 in the presence of the TLR3/dsRNA Complex Inhibitor (TLR3.CI) (30 nM). Total RNA was extracted from HBMEC and human brain tissues using the Trizol reagent (Life Technologies) according to the manufacturer's protocol. RNA was further cleaned using Total RNA cleanup kit (Qiagen, Valencia, CA, USA); RNA yield and quality were checked using a NanoDrop spectrophotometer (NanoDrop Technologies, Wilmington, DE) and for all samples absorbance ratio of 260/280 was ≥ 2. cDNA was generated from 1 μg RNA in a 20-μl reaction volume, using the Verso cDNA kit (Thermo Fisher, Waltham, MA, USA), according to the manufacturer's instructions. Reverse transcription was carried out for 30 min at 42°C.
Reverse Transcription (RT)-PCR
Two microliters of the cDNA obtained was used for RT-PCR, in a 20-μl reaction volume containing 50 U/ml Taq DNA polymerase supplied in a proprietary reaction buffer (pH 8.5) (Promega, Madison, WI, USA), 400 μM each dNTP, 3 mM MgCl 2 (all from Promega), and 25 μM human TLRs (1-10) specific primers (InvivoGen) ( Table 2 ). Positive controls consisted of PCR performed using 10 ng TLRs (1-10) cDNA provided by the manufacturer (InvivoGen). PCR was performed in a GeneAmp® PCR System 9700 (Applied Biosystems, Foster City, CA, USA), using the following conditions: 95°C for 2 min, followed by 35 cycles of 95°C for 30 s, 60°C for 30 s, 72°C for 2 min and 72°C for 5 min, and overnight incubation at 16°C. For endogenous control, additional PCR were performed using GAPDH-specific primers (forward primer: 5′-CGAGATCCCTCCAAAATCAA-3′; reverse primer: 5′-TGTGGTCATGAGTCCTTCCA-3′). Ten microliters of each PCR products was analyzed by electrophoresis on a 2% agarose gel containing ethidium bromide, and 
Protein Extraction and Western Blot Analysis
Following cellular treatment, protein extraction, quantification, and Western blot analysis were performed as previously described [26, 28, 29] . Briefly, cells were lysed using the mammalian cell lysis buffer CelLytic M (Sigma, St Louis, MO, USA), and protein quantified using the bicinchoninic acid assay as we previously described [26, 28, 29] . Protein (35 μg) was fractionated in a 10% sodium dodecyl sulfatepolyacrylamide gel electrophoresis and transferred onto nitrocellulose membranes. Membranes were blocked for 1 h with SuperBlock T-20 (Pierce, Rockford, IL, USA) and blotted for 2 h or overnight with monoclonal antibodies to TLR3, claudin-5 (Abcam), JNK, phopho-JNK, c-Jun, phospho-cJun (all from Cell Signaling Technology, Danvers, MA, USA). These primary antibodies were used at 1:1000 dilutions. Membranes were then washed, blotted for 1 h with horseradish peroxidase-conjugated secondary antibody, washed again, and visualized using the enhanced chemiluminescence (Pierce) and gel doc system (Syngene, Frederick, MD, USA). After each western blot experiment, membranes were stripped using the Restore Western Blot Stripping Buffer (Pierce) and re-blotted with β-actin antibody (Abcam) to confirm equal loading.
Interleukin-6 ELISA
Interleukin (IL)-6 expression and secretion was quantified using the BD OptEIA Human IL6 ELISA kit II (BD Biosciences, CA, USA) according to the manufacturer's protocol. Briefly, confluent HBMEC were treated with PIC (50 μl/ml), HIV-1 ADA (MOI: 0.01) and/or pharmacological inhibitors (Table 3 ) for 48 h. Controls consisted of untreated cells and cells treated with the TLR3/dsRNA Complex Inhibitor (TLR3.CI) (30 nM). Following cell treatment, culture supernatants were collected and further centrifuged for 5 min at 2350 g to remove any cellular debris, and 100 μl of each sample used for IL6 ELISA according to manufacturer's instructions. Absorbance readings were obtained using SpectraMax M5 ELISA plate reader (Molecular Devices, Sunnyvale, CA, USA). For each experiment, IL6 standards provided with the kit were used to generate a standard curve and determine IL6 concentrations in each sample. Each experimental condition was tested in duplicate or triplicate.
Monocyte Isolation and Labeling
Human monocytes were obtained from HIV-1/2 and hepatitis-B seronegative donor leukopaks, and separated by countercurrent centrifugal elutriation as previously described [26, 28, 30] . Cells were identified as > 98% pure monocytes by Wright staining and CD68 immunostaining (at 1:50 dilution) (Dako, Carpentaria, CA, USA). Monocytes were used for adhesion and transendothelial migration assays within 24 h of elutriation. Freshly elutriated monocytes were washed twice with pre-warmed (37°C) PBS, re-suspended in pre-warmed PBS containing 5 μM of 5-carboxyfluorescein diacetate, succinimidyl ester (CFDA-SE) (Life Technologies); 1 × 10 6 cells/ml, and incubated at 37°C, 5% CO 2 , for 15 min. Monocytes were then pelleted by centrifugation at 300 g for 10 min, re-suspended in pre-warmed media and incubated at 37°C, 5% CO 2 , for 30 min. CFDA-SE-labeled monocytes were washed three times with pre-warmed serum-free media before use for adhesion and migration assays.
Monocyte Adhesion and Migration Through In Vitro BBB Models
Adhesion and migration experiments were performed as we previously described [26, 28, 30] . Briefly, for adhesion assays, HBMEC were plated on 96-well collagen-coated black plates, and for migration assay, HBMEC were plated on collagencoated FluoroBlok-tinted tissue culture inserts (3-μm pore size; BD Biosciences). Confluent HBMEC were treated with PIC (50 μl/ml), HIV-1 ADA (MOI: 0.01), and/or pharmacological inhibitors (Table 3 ) for 24 or 48 h. Controls consisted of untreated HBMEC and cells treated with similar concentrations of pharmacological inhibitors for 24 or 48 h. Following treatment, HBMEC were rinsed three times to remove HIV-1, PIC, or pharmacological inhibitors. For adhesion assays, HBMEC were exposed to 2.5 × 10 5 CFDA-SE-labeled monocytes and incubated at 37°C, 5% CO 2 , for 15 min. After the 15 min incubation, HBMEC were washed 3 times with PBS and the number of adherent monocytes quantified by spectrophotometry (top readings, absorbance 494 nm; emission, 517 nm), with a standard curve derived from a serial dilution of a known number of CFDA-SE-labeled monocytes. For migration assays, following treatment and rinsing of HBMEC, 2.5 × 10 5 CFDA-SE-labeled monocytes were added to the upper chamber of the FluoroBlok inserts and allowed to migrate for 2 h (37°C, 5% CO2). The numbers of migrated monocytes were quantified by spectrophotometry (bottom readings, absorbance 494 nm; emission, 517 nm), with a standard curve derived from a serial dilution of a known number of CFDA SE-labeled monocytes.
Statistical Analyses
Data were analyzed by t test (two-tailed) for two-group comparisons and one-or two-way ANOVA followed by Tukey's multiple-comparisons tests using GraphPad Prism 5.0b. (GraphPad Software, La Jolla, CA, USA). Threshold of significance level was 0.05. Data are presented as means ± standard error of the mean.
Results
Expression of TLRs in Primary HBMEC
Our previous studies showed that signaling via TLRs was a major canonical pathway involved in HIV-induced activation of pro-inflammatory cytokines and chemokines in HBMEC, and BBB inflammation [25] . We performed RT-PCR to investigate the expression of TLRs in HBMEC and their role in HIV-induced BBB inflammation. We show that primary HBMEC express six TLRs (TRL3, 4, 5, 7, 9, 10) mRNA (Fig. 1a) . TLR3 was the most abundant TLR expressed and no mRNA for TLR1, 2, 6, or 8 was detected (Fig. 1a) . These results were confirmed by densitometry analyses of data from three independent experiments using HBMEC from three different human donors (Fig. 1b) .
Exposure of HBMEC to HIV-1 or TLR3 Ligands Increased TLR3 Transcription and Expression
To determine whether HIV or TLR3 ligands can alter TLR3 expression on the brain endothelium, we assessed TRL3 mRNA and proteins levels in HBMEC exposed to HIV-1 ADA (MOI: 0.01) or PIC (25 to 75 μg/ml) for 0.5 to 24 h. Exposure of HBMEC to HIV-1 or the TLR3 ligand PIC increased TLR3 transcription (Fig. 1c) , and densitometry analyses of data from three independent experiments using HBMEC from three different human donors, confirmed these results (Fig. 1d) . Exposure of HBMEC to HIV-1 or the TLR3 ligand PIC also increased TLR3 expression (Fig. 2) . Initial reduction in TLR3 expression was observed at 30 min HIV-1 exposure, but TLR3 levels gradually increased thereafter (Fig. 2a) , with timedependent increase in TLR3 expression observed from 12 to 48 h HIV-1 exposure (Fig. 2b) . Exposure of HBMEC to PIC for 24 h increased TLR3 expression, with maximal levels observed with 25 to 50 μg/ml PIC (Fig.  2c) . Densitometry analyses of data from three independent experiments using HBMEC from three different donors, confirmed that HIV-1 and PIC increased TLR3 expression (Fig. 2) .
Increased Transcription and Expression of TLR3 in Brain Tissues of HIV-1-Infected Humans
To determine whether HIV-1 infection alter TLR3 levels in the human brain, we analyzed brain tissues from 12 HIV-1/2-seronegative control subjects, 9 HIV-1-seropositive patients without evidence of HIVE or HAND, and 10 HIV-1-seropositive patients with HIVE and HAND. All brain tissues were from the cortical regions, with 28 of the 31 samples from the frontal cortex, 2 samples from the parietal cortex, and 1 sample from the temporal cortex. Table 1 shows the age, gender, clinical history, post-mortem interval (PMI) between the time of death and autopsy, and a summary of post-mortem findings for all 31 human subjects. No significant differences were detected in age and PMI between the seronegative, HIV-1-infected, or HIVE groups. For seronegative controls, HIV-1-infected, and HIVE patients, the age ranges in years (and means ± standard deviations) were respectively 32 to 72 (mean: 52±13.4), 27 to 54 (mean: 41.78 ±8.8), and 30 to 52 (mean: 40.6±7.76). For seronegative controls, HIV-1-infected, and HIVE patients, the PMI ranges in hours (and means ± standard deviations) were respectively 3 to 8.5 (mean: 4.6±1.6), 2.75 to 15 (mean: 8.5±4), and 4 to 21 (mean: 9.45±5.16).
Quantitative real-time PCR showed significant upregulation of TLR3 mRNA transcripts in brain tissues from HIV-1-infected humans, with the highest TLR3 mRNA levels in brain tissues of patients with HIVE/HAND (Fig. 3a, b) . To further investigate the effects of HIV-1 infection on TLR3 expression in the human BBB in vivo, we analyzed brain tissue sections from seronegative controls, HIV-infected and HIVE patients by confocal microscopy. Data showed TLR3 expression on the brain blood vessels of seronegative controls (Fig. 3c-f , yellow arrows), HIV-positive (Fig. 3g-j, yellow arrows) and HIVE ( Fig. 3k -n, yellow arrows) patients, with higher TLR3 expression in the blood vessels and tight junction strands of HIV+ and HIVE patients brains, as demonstrated by increased staining intensity. Brain tissues from HIVpositive and HIVE patients also showed mononuclear phagocytes expressing TLR3 crossing the blood vessels (Fig. 3, orange arrows) .
HIV-1 and TLR3 Ligands Upregulate IL6 Expression in HBMEC
To determine whether PIC-and HIV-1-induced increase in TLR3 expression in HBMEC (Figs. 1 and 2 ) could be associated with increased BBB inflammation, we analyzed the effect of TLR3 ligands and HIV-1 on IL6 expression and secretion in HBMEC. Studies using HBMEC from three different human donors (Fig. 4a-c) showed that PIC at 0.5 to 75 μg/ml increased IL6 expression and secretion in primary HBMEC by 6 to 127-fold (Fig.  4a-c , P < 0.001). Studies using HBMEC from the third donor showed that the TLR3/dsRNA complex inhibitor (TLR3.CI) blocked both PIC-and HIV-1-induced IL6 expression ( Fig. 4c , P < 0.001). To determine whether HIV-1-and PIC-induced IL6 expression was associated with increased IL6 transcription, we used real-time PCR to quantify IL6 mRNA in HBMEC exposed to HIV-1 (MOI: 0.01) and PIC (50 μg/ml) for 2 to 24 h. Both PIC and HIV-1 induced a time-dependent increase in IL6 transcription in HBMEC, with the highest IL6 mRNA levels observed from 24 h HIV-1 or PIC exposure (Fig. 5a ). The IL6 promoter contains several cis-acting response elements that regulate its transcription and expression. These included the activator protein-1 (AP-1), NFκB, STATs, and the cAMP response element binding protein (CREB/CEBP) [31] [32] [33] . Therefore, we analyzed the effects of HIV-1 and TLR3 ligands on the expression of these transcription factors. Compared to untreated controls both PIC and HIV-1 significantly increased Additional controls consisted of Western blot analyses with β-actin antibodies; densitometry analyses of data from three independent experiments using HBMEC from three different human donors, confirmed that HIV-1 and PIC increased TLR3 expression (a-c). kDa: kilodalton. *P < 0.05, ***P < 0.001 Fig. 1 TLR3 mRNA is the most abundant TLR transcript expressed on HBMEC, and HIV-1 and TRL3 ligands increased TLR3 transcription. a Semi-quantitative RT-PCR using primers specific for TLRs 1-10 showed mRNA for TLR3, 4, 5, 7, 9, and 10 in HBMEC, and TLR3 were the most abundant. hTLR PCs: human TLRs positive controls; RT-PCR was performed using 10 ng TLRs (1-10) cDNA from InvivoGen. b Densitometry analyses of RT-PCR data from three independent experiments using HBMEC from three different human donors. c Exposure of HBMEC to HIV-1 ADA (MOI: 0.01) or PIC for 24 h increased TLR3 transcription, and densitometry analyses of data from three independent experiments using HBMEC from three different human donors, confirmed these results (d). Additional controls consisted of RT-PCR with GAPDH primers (a, c). M: molecular weight marker; bp: base pairs; *P < 0.05, ***P < 0.001 JUN, RELB, CEBPA, CEBPG, and STAT1 transcription in HBMEC (Fig. 5b-f) . PIC-and HIV-1-induced expression of these transcription factors was mostly time-dependent, with the highest mRNA levels observed at 24 h exposure ( Fig.  5b-f ). Compared to untreated controls, exposure of HBMEC to PIC for 2 to 24 h increased IL6, JUN, RELB, CEBPA, CEBPG, and STAT1 mRNA levels respectively by 9 to 108.6-fold (Fig. 5a ), 3 to 4 fold (Fig. 5b ), 1.7 to 29-fold ( Fig. 5c ), 2 to 4.2-fold ( Fig. 5d ), 1.97 to 6.26-fold (Fig. 5e ), and 9 to 108.6-fold (Fig. 5f ). Exposure of HBMEC to HIV-1 for 2 to 24 h increased IL6, JUN, RELB, CEBPA, CEBPG, and STAT1 and mRNA levels respectively by 27.8 to 150-fold (Fig. 5a ), 4 to 10.78 fold (Fig. 5b) , 13 to 54.78-fold (Fig. 5c ), 1.92 to 12-fold ( Fig. 5d ), 3.65 to 14.8-fold (Fig. 5e) , and 27.8 to 150-fold (Fig. 5f ).
TLR3/dsRNA Complex Inhibitors Blocked both TLR3 Ligands-and HIV-1-Induced Upregulation of mRNA Transcripts for IL6 and Transcription Factors Associated with the TAK1 and JNK Pathways
To confirm the involvement of TLR3 in HIV-1-induced upregulation of mRNA transcripts for IL6 and the transcription factors identified above (Fig. 5) , we performed real-time PCR to quantify their mRNA levels in HBMEC exposed for 24 h to (Fig. 6) . The TLR3.CI blocked both HIV-1-and PIC-induced transcription of IL6 (Fig. 6a , P < 0.05 and P < 0.01), JUN ( Fig.  6b , P < 0.001), RELB ( Fig. 6c , P < 0.001), CEBPA ( Fig. 6d , P < 0.05), CEBPG ( Fig. 6e , P < 0.01), and STAT1 ( Fig. 6f , P < 0.001).
HIV-1 and TLR3 Ligands Induced Phosphorylation of c-Jun and JNK in HBMEC
Because HIV-1 and TLR3 ligands upregulates the transcription factors associated with the JNK pathways (Figs. 5 and 6), we analyzed the effects of HIV-1 and PIC on c-Jun and JNK activation in HBMEC. Exposure of HBMEC to both PIC (Fig. 7a) and HIV-1 (Fig. 7b) induced the phosphorylation of c-Jun at serine-63 (Ser63). PIC-and HIV-1-induced c-Jun phosphorylation occurred as early as 5 min and gradually increased for up to 2 h, with maximal phosphorylation observed at 2 h (Fig. 7a, b ). Both PIC (Fig. 7a) and HIV-1 (Fig. 7b) increased the phosphorylation of SAPK/JNK at Thr183/Tyr185; with PIC-induced SAPK/JNK phosphorylation occurring as early as 5 min following PIC exposure (Fig.  7a) , and HIV-1-induced SAPK/JNK phosphorylation starting at 30 min following viral exposure (Fig. 7b) . Repeated experiments using HBMEC from different donors confirmed these results, and showed that TLR3.CI inhibited both HIV-1-and PIC-induced phosphorylation of c-Jun, and also inhibited HIV-1-and PIC-induced phosphorylation of SAPK/JNK (Fig. 7c) . (Fig. 8a) , whereas the inhibitor of c-Jun/JNK complex (420130), the inhibitor of NFκB transcriptional activation (481406), the inhibitor of AP-1 transcription (SR11302), and the IRAK1/4 inhibitor only partially reduced or had no major effect on PIC-induced IL6 expression (Fig. 8b) . The ATPcompetitive JNK inhibitor (420129), the TAK1/MKK7 inhibitor (5ZO), and the IRAK1/4 inhibitor blocked HIV-1-induced IL6 expression and secretion (Fig. 8c) ; whereas the JNK inhibitor 420119, the inhibitor of c-Jun/JNK complex (420130), the inhibitor of NFκB transcriptional activation (481406), and the inhibitor of AP-1 transcription (SR11302) had no major effect on HIV-1-induced IL6 expression (Fig.  8c) .
Effects of HIV-1 and TLR3 Ligands on the Blood-Brain Barrier Properties and Function
We previously demonstrated that HIV-1 and viral factors impair the BBB properties and function, and this was associated with decreased expression of tight junction proteins, increased adhesion and migration of human mononuclear phagocytes through the BBB [26, 29, 30] . To determine whether this involves TLR3, we assessed the effects of HIV-1 and TLR3 ligands on claudin-5 expression in primary HBMEC, and monocytes adhesion and migration through in vitro BBB models. Exposure of HBMEC to HIV-1 and PIC (50 μg/ml) for 24 h increased monocytes adhesion (by 4-and 3.5-fold respectively, Fig. 9a ) and transmigration through the BBB (Fig. 9f) . PIC-induced monocyte adhesion and trans-endothelial migration decreased over time, with less adhesion and migration after 48 h (Fig. 9d,  e ), compared to 24 h PIC treatment (Fig. 9a, b) . Similarly, 48 h PIC treatment of HBMEC did not significantly altered claudin-5 expression (Fig. 9f) , whereas 24 h PIC treatment significantly decreased claudin-5 expression (Fig. 9c,  P<0 .001). The TLR3.CI decreased HIV-1-induced monocytes adhesion (by 2.4 to 4.6-fold, Fig. 9a,d ), BBB transmigration (by 3 to 4-fold, Fig. 9b , e) (P < 0.001), and abrogated HIV-1-induced decrease in claudin-5 expression (Fig. 9c,   f ). TLR3.CI also decreased PIC-induced monocytes adhesion (by 1.4 to 2.4-fold, Fig. 8a, c) , transmigration through the BBB (by 1.6 to 4-fold, Fig. 8b, d ) (P < 0.001), and abrogated PIC-induced downregulation of claudin-5 expression (Fig. 9c, f) .
Data in Figs 5, 6 , and 8 showed that the JNK pathways mediated HIV-1-and TLR3 ligands-induced inflammation. To determine whether this pathway was also involved in HIV-1-and PIC-induced alterations in BBB properties and function, we assessed the effects of an ATP-competitive JNK inhibitor (420129) on monocytes adhesion, BBB transmigration, and endothelial claudin-5 expression. This JNK inhibitor reduced HIV-1-induced monocytes adhesion (by 2-to 3.3-fold, Fig. 9a, d ) and transmigration through the BBB (by 2-to 6-fold, Fig.  9b , e) (P < 0.001). It significantly reduced HIV-1-induced decrease of claudin-5 expression (by 2.2-to 2.5-fold, Fig. 9c, f) . This JNK inhibitor also reduced PIC-induced monocytes adhesion (by 1.7-to 2.5-fold, , and STAT1 (f). *P < 0.05, **P < 0.01, ***P < 0.001. These are representative data from three independent experiments using HBMEC from three different human donors Fig. 9a, d) , transmigration through the BBB (by 1.95-to 2.3-fold, Fig. 9b , e) (P < 0.001), and also abrogated PICinduced decrease in claudin-5 expression (Fig. 9c,  P<0 .05). Densitometry analyses of data from two independent experiments using HBMEC from two different donors, confirmed HIV-1 and PIC-induced downregulation of claudin-5 expression, as well as the protective effects of the TLR3.CI and JNK inhibitor (Fig. 9c, f) .
Discussion
In HIV-infected individuals, the BBB is exposed to virions and viral products from the systemic circulation, and there is Fig. 8 The JNK and TAK1/MKK7 pathways mediate TLR3 ligands-and HIV-1-induced IL6 expression HBMEC. a The JNK inhibitor 420119, the ATP-competitive JNK inhibitor 420129, and the TAK1/MKK7 inhibitor 5ZO blocked PIC induced IL6 expression and secretion. b PIC induced IL6 expression was reduced by the inhibitor of AP-1 transcriptional activity SR11302, whereas the inhibitor of NFκB transcriptional activation 481406, the IRAK1/4 inhibitor, and the inhibitor of c-Jun/JNK complex 420130 had minimal to no effect. c The ATP-competitive JNK inhibitor 420129, the IRAK1/4 inhibitor, and the TAK1/MKK7 inhibitor 5ZO blocked HIV-1-induced IL6 expression and secretion; whereas the JNK inhibitor 420119, the inhibitor of c-Jun/JNK complex 420130, the inhibitor of NFκB transcriptional activation 481406, and the inhibitor of AP-1 transcriptional activity SR11302, had minimal to no effect. *P < 0.05, **P < 0.01, ***P < 0.001 [21] [22] [23] [24] . This HIV-1-induced BBB injury is associated with signaling via IL6 and TLRs [25] , and the present study show that primary HBMEC, the major component of the BBB, express TLR3, 4, 5, 7, 9, and 10. We also show that TLR3 was the most abundant TLR expressed in these cells. It has also been shown that the human cerebral endothelial cell line hCMEC/D3 express mRNA for TLR2, 3, 4, and 6 [34] and that primary rat cerebral EC express mRNA for TRL2, 3, and 6 [34] . The fact that TLR2 and 6 are expressed in the hCMEC/ D3 cell line and rat cerebral EC but not in primary HBMEC; and that TLR5, 7, 9, and 10 are expressed in primary HBMEC, but not in hCMEC/D3 or rat cerebral EC, shows heterogeneity in TLRs expression on blood vessels, with differential expression in primary brain EC compared to cell lines, and in EC from animals brain vessels compared to EC from human brain vessels. EC from other vascular beds also express TLRs. Human lung and dermal EC [35] , as well as human choroidal and retinal EC [36] express TLR1, 2, 3, 4, 5, 6, and 9 [35, 36] .
TLR3 can be activated by viral dsRNA [6] , viral ssRNA [7] , or by dsRNA generated by RNA polymerases as intermediates during replication of positive-sense ssRNA viruses [12, 37, 38] . HIV-1 is a positive-sense ssRNA virus; in HIVinfected subjects, the BBB is constantly exposed to virus from the peripheral blood, which could also activate TLR3. In the current study, we showed that exposure of HBMEC to HIV-1 or TLR3 ligands increased TLR3 transcription and expression. Significantly, we showed increased transcription and expression of TLR3 in brain tissues from HIV-1-infected humans, with higher TLR3 expression in blood vessels and , and claudin-5 downregulation (c, f). ***P < 0.001. Controls consisted of untreated HBMEC, and HBMEC exposed only to TLR3.CI or the JNK inhibitor. These controls showed no alteration in BBB function. These are representative data from two independent experiments using HBMEC from two or three different human donors tight junction strands of HIV+ and HIVE patients. This indicates that HIV-1 CNS infection is associated with increased TLR3 expression in the brain, and that HIV-induced encephalitis further increased TLR3 expression. Our data showing expression of TLR3 in mononuclear phagocytes on blood vessels suggest that increased TLR3 expression in HIV-1 infected subjects was associated with increased infiltration of blood mononuclear phagocytes into the CNS. These data demonstrate the involvement of TLR3 in HIV-1-induced BBB injury and HIVE, and are in agreement with other studies implicating TLR3 in HIV/AIDS pathogenesis. In fact, there is increased TLR3 expression in peripheral blood mononuclear cells of HIV-1 infected patients [39] , with the highest TLR3 levels in cells from patients with advanced AIDS and higher viral load [40] .
Human studies showed that increased plasma or serum IL6 levels in HIV-infected subjects is associated with higher viremia, faster progression to AIDS, worse clinical outcomes and high mortality [41] [42] [43] . We previously showed that HIVinfection and HAND was associated with increased expression of IL6 in human brain tissues and the BBB [25, 26, 28, 29] . Our current study shows that exposure of primary HBMEC to HIV-1 or TLR3 ligands increased IL6 transcription and expression. This involvement of TLR3 in HIVmediated IL6 production and BBB inflammation was further confirmed by data showing that inhibitors of TLR3/dsRNA complex blocked both HIV-1-and PIC-induced IL6 transcription and expression. There is evidence that TLR3 activation of EC from other vascular beds also induce inflammation in humans. Exposure of human glomerular EC [44] , lung EC [35, 45] , dermal microvascular EC [35] , choroidal and retinal EC [36] , and coronary artery and umbilical vein EC [46] to PIC increased the expression of IL6 [35, 36, 44, 45] , as well as IL8 and IP10 in vitro and in vivo [45, 46] ; TNFα, IFNβ, CCL2, CCL5, and CXCL10 [44] .
The IL6 gene has functional cis-regulatory elements that contain binding sites for NFκB, CEBP, AP-1, STATs, and CEBPs [31] [32] [33] . In the current study, we showed that in addition to increasing IL6 transcription and expression, exposure of HBMEC to HIV-1 or PIC significantly upregulated the transcription factors JUN, RELB, CEBPA, CEBPG, and STAT1. TLR3 dimerizes to form a signaling complex [47] and ligands bind to the TLR3 dimer via its N-terminal ectodomain [48] . Ligand binding results in a conformational change and recruitment of Toll/IL-1 receptor domaincontaining adaptor inducing IFN-β (TRIF), which then triggers a signaling cascade that results in expression of INF-β or proinflammatory cytokines [49] . Our data confirm the specificity of TLR3 pathways in PIC-and HIV-1-induced IL6 expression, as we demonstrate that both HIV-1-and PICinduced IL6 expression and secretion could be blocked by an inhibitor of the TLR3/dsRNA complex (TLR3.CI) that specifically antagonize TLR3 signaling by blocking the binding of dsRNA to TLR3. TLR3.CI also blocked HIV-1-and PIC-induced upregulation of mRNA transcripts for IL6, JUN, RELB, CEBPA, CEBPG, and STAT1. c-Jun dimerizes with c-Fos to form AP-1 [50] ; and c-Jun is activated through phosphorylation by the JNK pathways [50, 51] . We show that TLR3.CI also blocked both HIV-1-and PIC-induced phosphorylation of c-jun and JNK. These data further confirmed the involvement of JNK pathways downstream of TLR3 in HIV-1-induced BBB dysfunction.
HIV-1-induced and TLR3-mediated IL6 expression in HBMEC was blocked by 5ZO, an ATP-dependent and competitive inhibitor of TAK1 and the MAP kinases MKK7, MEK1 and ERK2; and was also blocked by 420129, an ATP-dependent and competitive JNK inhibitor. In the MAPK/JNK pathways, stress signal activates small GTPases such as Rac1 and Rho; activated GTPase then stimulate MAPKKK, which phosphorylates MKK4 or MKK7 [52] [53] [54] . Following activation, MKK4/7 phosphorylates and activates JNK. Activated JNKs form dimers, translocate to the nucleus, bind to the c-Jun transcriptional domain, and phosphorylate c-Jun at serine or threonine residues [52, 54] . Thus, JNK regulates c-Jun/AP-1 activity and it has been shown that phosphorylation of c-Jun at Ser63 or Ser73 increases the transcription of downstream target genes [50] [51] [52] [53] . This was confirmed by our present data showing that exposure of HBMEC to HIV-1 and TLR3 ligands induced Ser63 phosphorylation of c-Jun and Thr183/Tyr185 phosphorylation of JNK, and that this was associated with increased IL6 expression. HIV-1-and PIC-induced IL6 expression was blocked by TLR3.CI and by pharmacological inhibitors of JNK and TAK1/MKK7, all downstream effectors of TLR3 signaling (Fig. 10) . The MAP kinases TAK1, MKK7, MEK1, and ERK2 all contain a cysteine residue in their ATP-binding site; suggesting that 5ZO and JNK inhibitors may block IL6 expression by interfering with cysteine residues in the ATP-binding region of these kinases. This would suggest that a region on these kinases ATP-binding site is involved in HIV-1-induced and TLR3-mediated endothelial inflammation and BBB dysfunction. The fact that the ATP-dependent and competitive JNK inhibitor 420129 blocked both PIC-and HIV-1-induced IL6 expression and secretion while the non-ATP-dependent JNK inhibitor 420119 only blocked PIC and had no effect on HIV-1-induced IL6 expression suggests that TLR3-mediated IL6 expression can occur via ATP-dependent or -independent activation of JNK, whereas HIV-1-induced IL6 expression on the brain endothelium occur strictly via ATP-dependent activation of JNK.
Functional studies showed that HIV-1 and PIC decreased claudin-5 expression in HBMEC, significantly increased monocytes adhesion and migration through the BBB, and that the ATP-dependent JNK inhibitor 420129 and TLR3.CI blocked both PIC-and HIV-1-induced monocytes adhesion and trans-endothelial migration, and abrogated PIC-and HIV-1-induced claudin-5 downregulation. This suggests that both HIV-1 and TLR3 ligands use similar TAK1-and JNKdependent pathways upstream to induce IL6 expression in HBMEC and BBB dysfunction (Fig. 10) ; and that this occurs through ATP-dependent mechanisms. Inhibitors of IRAK1/4, downstream effectors of TLR signaling, blocked HIV-1-induced IL6 expression, but only partially diminished PICinduced IL6 expression. Activated JNK phosphorylates cJun, which dimerizes with c-Fos to form AP-1 [50, 51] . The inhibitor of c-Jun/JNK complex formation, the inhibitor of AP-1 transcriptional activity, and the inhibitor of NFκB transcriptional activation had no major effect on HIV-1-or PICinduced IL6 expression. This suggests that HIV-1-induced and TLR3-mediated IL6 expression and inflammation occurs principally via TAK1 and JNK pathways, not by affecting the c-Jun/JNK complex or AP1 transcriptional activity, nor by affecting NFκB transcriptional activation. Antibodies to IL6 or IL6 receptors are clinically used for the treatment of inflammatory diseases [55] [56] [57] . Our current study provides novel insights into the molecular basis for HIV-1-induced and TLR3-mediated IL6 expression in HBMEC, BBB dysfunction and CNS injury. The data suggests that targeting TLR3, TAK1, and JNK signaling pathways could provide a therapeutic approach for preventing BBB inflammation, dysfunction and CNS injury in HIV/AIDS. ligands-mediated effects. The blue rectangular boxes indicate compounds that inhibited HIV-1-mediated IL6 expression, but had minimal effects on PIC-mediated effects. The brown color rectangular boxes indicate compounds that blocked or significantly diminished TLR3 ligands-induced IL6 expression but had no effects on HIV-1-mediated effects. The black color boxes indicate compounds that had no effect on HIV-1 or TLR3 ligands-mediated effects.
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